Chordia Therapeutics Inc.
190A.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.29B
Close$
Share Statistics
| Market cap | $4.29 Billion |
|---|---|
| Enterprise Value | $1.78 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-26.03 |
| Beta | 3.13 |
| Outstanding Shares | 75,261,951 |
Return
| Return on Equity | -61.47% |
|---|---|
| Return on Assets | -55.46% |
| Return on Invested Capital | -61.94% |
Valuation & Multiples
| P/E Ratio | -2.84 |
|---|---|
| PEG | 133.23 |
| Price to Sales | - |
| Price to Book Ratio | 1.9 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.23 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Chordia Therapeutics Inc.
20 employees
CEO: Hiroshi Miyake Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treat...